

# A REVIEW ON CONTROLLED RELEASE BEADS OF ANTI-MICROBIAL DRUG

<sup>1</sup>Navneet Verma, <sup>2</sup>Sunil Kumar Tiwari, <sup>3</sup>Vijay Sharma, <sup>4</sup>Arvind Raghav

<sup>1</sup>Faculty of Pharmacy, IFTM University, Moradabad, U.P. India.

<sup>2</sup>School of Pharmaceutical Sciences, IFTM University, Moradabad, U.P. India.

<sup>3</sup>Faculty of Pharmacy, IFTM University, Moradabad, U.P. India.

<sup>4</sup>School of Pharmaceutical Sciences, IFTM University, Moradabad, U.P. India.

## Abstract:

Alginate and chitosan polymers are widely used in the preparation of drug release. These two polymers can be used together or separately to form modified drug-loaded release beads. A method of ionotropic gelation and subtle modification in various ways is used to fix these beads of different characteristics. Bead characteristics such as morphology, buoyancy, inflammatory environment, drug efficacy, marketing, and liberal behavior are important and the therapeutic use of various bead modifications can be great for underwater soluble drugs, half-life biological Health, requires direct organ guidance, and has natural protein. The need for longer and better control over drug administration has increased the need for stitched polymers. Hydrocolloids such as alginate can play an important role in the production of a controlled by-product. At low pH the flow of, alginic acid leads to the formation of a high-viscosity “acid gel.” Alginate is also easily applied to the gel in the presence of a divalent cation like calcium ion. This review discusses the current use the future opportunities for alginate as a tool in drug development.

**Keywords:** Alginate, chitosan, Controlled Release, Drug Delivery, ionotropic gelation, beads.


## INTRODUCTION

Conventional drug delivery systems (DDS) have very limited prescriptions for drug distribution and there is almost no effective targeting target command. This type of dose will lead to unexpected changes in plasma concentrations [1]. To achieve rapid and complete scheduled absorption of drugs, several common oral drugs, such as capsules and tablets, are designed for the administration of an active drug directly following oral administration [2].

Alginate, a naturally occurring biopolymer, is gaining increasing popularity in a variety of fields. It has been used successfully for many years in the food and beverage industry as a stabilizing agent, gelling agent, and colloidal stabilizer. It also has a few unique areas that have opened the field for its use as an entry matrix and/or delivery of a variety of proteins, drugs, and cells. These properties include:

- (i) the surface of the water relative to the inside of the matrix;
- (ii) the process of mixing cooler temperatures in a room free of organic solvents;
- (iii) a very high gel that allows for high levels of distribution of macromolecules;
- (iv) the ability to control this porosity through simple integration processes; and
- (v) disintegration and degeneration of the system under normal physiological conditions [3].

Alginate is a water-soluble, polyanionic line; polysaccharide extracted from the black sea and composed of 1-4 alternating blocks linked to the residues of  $\alpha$ -L-guluronic and  $\beta$ -D-mannuronic acid [4]. The gel beads are prepared by alginate sol-gel modification which is introduced by combining alginate with divalent cations such as  $\text{Ca}^{2+}$ ,  $\text{Zn}^{2+}$ . Guluronic acid is responsible for gel formation by alginate and cations of solution. The alginate matrix that encloses the open lattice structure forms narrow beads. Beads have a low storage capacity for combining low molecular weight with a water-soluble drug [5]. Chitosan is a biocompatible, biodegradable, nontoxic, linear co-polymer polysaccharide, consisting of  $\beta$  (1–4) -linked 2-amino-2-deoxy-D-glucose (D-glucosamine) and 2-acetamido-2 -deoxy- D-glucose units (N-acetyl-D-glucosamine) and has a structural similarity to cellulose (made up of D-glucose units attached to  $\beta$  (1–4)). Chitosan is an N-deacetylated release from chitin, although this N-deacetylation is not complete, with several amino groups exposed making it a polycationic polysaccharide. Depending on the degree/extent of deacetylation, different levels of chitosan are available. Due to its gel-based structure, it has been used in the development of a drug delivery system [5]. The most effective drug delivery beads can be made using your combination of both alginate and chitosan. The interaction between alginate and chitosan has been systematically investigated. Their polyelectrolyte complex has been widely used to detect devices for controlled drug release [6].



**Figure 1: Classification of Modified Release Drug Delivery System**

### **Advantages of CDDS [7-9].**


CDDS has many benefits over traditional therapy:

- Good plasma level
- Improving patient compliance
- Low dose and toxicity
- Opportunities for identification
- The frequency of medication administration is reduced.
- Patient compliance should be improved.
- Better control can be achieved by absorbing the drug
- Improving small volume supply capacity
- Minimize or remove local effects
- Reduce or suppress system side effects

- Reduce the accumulation of over-the-counter drugs.
- Improve the effectiveness of treatment
- Prompt treatment or follow-up
- Improvement/control means that fluctuations in medication levels are reduced.
- Improving the bioavailability of certain drugs
- Use special effects, for example, continuous release of aspirin, until bedtime for morning rheumatoid arthritis by dosing.
- Difficult drug delivery: lazy release of soluble water drugs, immediate release of drugs with low solubility.
- Reducing the cost of health care

### Disadvantages of CDDS [10]

- Delay in drug action
- Chances of weight loss in the event of a malformation
- Increased dependence on the duration of GI duration
- The right to change the dose with a little fidelity in some cases
- Unit capacity costs are high compared to normal volumes
- Not all instructions are appropriate for ER capacity building.



**Figure 2: General Mechanism of CDDS**

### FACTORS AFFECTING ORAL-CONTROLLED RELEASE PRODUCTS [11-15]

**Dose size:** The upper range to administer the drugs through the oral route, commonly for a single dose is 0.5-1 gram.

**Ionization and Dissociation constant:** In accordance with the pH partition hypothesis, unmodified drug types will be absorbed by various body tissues first, so it is very important to consider the interaction between the variability of the separation and the place where the drug will be absorbed. In traditional dosage forms, the drug dissolves completely in the stomach and is absorbed completely in the small intestine, but in a controlled system, the drug may be in a

solid state of the gut, which means that the drug melts and tends to change over time. its release. Those compounds that are less soluble, should be controlled naturally because their dosage release time, in the GI (GIT) form, will be restricted by drug termination. 0.1 mg/ml is indicated as a low melting point of the drug to be formulated for CR.


**Partition coefficient:** A compound with a high partition coefficient tends to melt lipid thus having a higher bioavailability, while a lower partition coefficient leads to lower penetration of compounds into the membrane which means poor bioavailability.

**Drug stability:** Drugs that show instability in the gastrointestinal tract are administered in a controlled manner to reach the gut through a delayed release this can also exacerbate the damage to the intestinal tract. Therefore, often the unstable drugs in the GIT tract are not suitable for CR. Cells Size: Ingredients with high molecular weight are not the ideal candidates for CR. Diffusivity is the function of the penetrating drug depending on the size and structure of the membrane.

**Biological Half-life:** In CR, it is included in the life expectancy of fewer than 8 hours in a good candidate position. Although drugs with a half-life of fewer than 2 hours require high doses of the drug in CR. Ingredients with a life expectancy of more than 8 hours are not used in CR. Therefore, drugs with a shorter half-life or higher are not suitable for CR form.

**Metabolism:** Combined drug metabolism is considered in the formation of CR products. CR forms can be upgraded if location, level, etc. metabolic reactions are known.

## ORAL CONTROLLED-RELEASE MECHANISM



**Figure 3:** Drug delivery systems are developed with a variety of release control strategies. First, the tree spreads into a matrix-based system through a winding web of connected holes. The drug travels over the non-permeable membrane of the tank. When pores are formed and things deteriorate in a damaged DDS, the drug is released. Similarly, an object is released at the top during DDS eroding and melting. In response to osmotic gradients, osmotic pumps

deliberately release drugs through one or more small holes in the impermeable membrane. Finally, hydrogel DDS delivers drugs to a network that limits its mesh size based on hydration and polymer formulation. **Figure 3** shows the different-different release mechanism of CDDS.

## **METHOD OF PREPARATION OF BEADS**

The beads can be prepared by the ionotropic gelation method [16]. The method has been modified as per the need mentioned below.

- i. Syringe or dropper method
- ii. Extrusion method
- iii. Laminar jet break-up or prilling method

### **Ionotropic gelation method**

This involves the formation of hydrogel beads by administering an alginate solution with a solution containing polyvalent (especially fragmented ions). Polyvalent ions assist in the formation of a gel by forming a bond with alginate. This is the most common method used and can be modified in many different ways to bring about the desired condition, size, and treatment effects [17 - 20].

a) Sodium alginate solution is prepared (different concentrations). In that solution, the drug (if necessary in a suitable vehicle) in different areas is added. The mixture is stirred and allowed to stand for the required time. The mixture is then thrown into a solution containing divalent ions (different concentrations) and if necessary in different pH conditions. Such beads are washed (different solutions) and dried (different conditions). Such wet beads can be coated with polymers such as chitosan and dried to prepare the release.

(b) The sodium alginate solution is mixed with the drug solution and a chitosan-like polymer is added to it. The mixture is then ground with a divalent ion solution as above

(c) Another modification may be the addition of an alginate solution to a mixture of divalent ion salts and polymer (chitosan). The formed beads are then passed through the same processes.

### **Extrusion method**

Extrusion is the process of creating an object of a fixed size by pushing or drawing objects with the desired cross dice. The sodium alginate solution is mixed with the drug solution and is injected into a dissolved metal salt solution by removing it through a silicone tube using a peristaltic pump. This method can be used for all of the above preparations of the drug, alginate solution, chitosan solution, and gelling polyvalent electrolyte solution. The resulting beads are sorted and dried at high temperatures.

### **Prilling method**

It is a method of preparing small droplets with air flowing upwards when mixed with a solution of falling sodium alginate [21]. Drops of solution are used to make beads using a vibrating mouthpiece that pumps through a pipe at different rates in a saline metal solution. Such beads are filtered and dried at high temperatures. This method has been widely used to obtain microparticles of small diameter and high efficiency of encapsulation, especially in the biotechnology of cell reinforcement.

## **CHARACTERIZATION OF BEADS**

### **Buoyancy**

The buoyancy of direct abdominal adjustment is measured using a standard pycnometer or electronic densimeter. The gas pycnometer compares the pressure change caused by a modified change in a closed volume containing a reference (usually a known steel sphere) with a change in pressure caused by the sample under similar conditions. The difference in pressure change represents the sample volume compared to the reference sphere [22]. Reducing congestion beads over buoyancy. Beads that contain medicine and vegetable oil in the float provide a particular delivery to the stomach [23].

### **Morphological studies/particle size using a scanning electron microscope**

Dried beads with a low alginate concentration lose a round shape when dried, but high-concentrated beads retain shape. Beads from path (i) b indicate an increasing size, but lose a circular structure when dried. Beads from (i) calcium alginate beads covered with chitosan (polymer) show a circular structure in both dry and wet conditions. But sometimes high polymer coating leads to cracks and holes in the surface, [24] and even ethanol drying reduces facial stiffness [25]. Some authors have observed circular beads where eudragit, acrylic polymer, is used to fix calcium alginate beads and when the beads are bonded with chitosan [26].

### **Swelling studies**

Bead swelling behavior is studied by measuring the width of the beads with a digital camera. The size of the swelling is expressed by the average diameter of the swollen beads to the average diameter of the beads suspended before the test and the increase in width is determined. Chitosan-bound beads swell less than non-woven ones due to the formation of the skin layer with chitosan [24]. Inflammatory behavior depends on pH. The beads swell slightly in the stomach, but the swelling gradually increases in the pH of the intestines and the size of the colon for direct colon delivery [26].

### **Entrapping efficiency**

The efficiency of a water-soluble drug is low as the area used is full of water and the drug will lose a lot in the middle. Increasing healing time, and reducing seizures [20]. Water-soluble drugs are effective in catching. When the tree is full, it will be closed. Increased coating of the coating polymer also increases the efficiency of penetration [25,26].

### **Release behavior**

The drug release is determined by introducing beads into the dispersed media made of the bath at  $37 \pm 0.5$  ° C,  $37 \pm 0.1$  ° C  $37$  ° C and stirred at 50 rpm. Using XXIII USP basketball equipment, Japan Pharmacopoeia 13th edition (JP XIII) paddle-type test apparatus is used. Samples were extracted periodically and spectrophotometrically tested for high wave absorption wavelengths. The percentage of drug withdrawal is calculated with respect to the drug content of the beads. The drug content is expressed as a percentage of the drug added to the weight of the bead unit. Tests were performed three times and the results were limited [27].

Dry beads show reduced drug release with increased concentration of chitosan, but increased alginate exposure reduced release from lower chitosan concentration and increased release with higher chitosan concentration. The oily beads in it release the drug gradually. With dried beads, due to the destruction of the alginate chitosan film, the drug release was over. Increased concentrated chitosan concentration showed a decrease in drug release, and an increase in drug exposure increased drug release.

## CONCLUSION

Drug-laden beads of alginate, chitosan, and alginate bound or mixed with chitosan may be particularly important in the delivery of the drug via the oral route and other routes as forms of continuous and controlled release doses. Desirable results in the release of drugs and the amount of treatment may be achieved by adjusting the various components and/or their concentration. Since these beads are nontoxic, decaying, and biologically active, they should be carefully considered for use in the delivery of drugs in a controlled and continuous manner. A molecule can be properly made to use several. The delivery of polymer-controlled drugs is still in the development phase. A new approach in this field is the development of systems that can adjust drug release according to body needs (e.g., pH response systems based on polymer inflammation, delivery systems activated by magnets). Alginate will also have the physicochemical properties needed to make it an important contribution to this area of future research.

## REFERENCE

1. Gupta, B.P., Thakur, N., Jain, N.P., Banweer, J.&Jain,S. (2010). Osmotically Controlled Drug Delivery System with Associated Drugs. *J. Pharm. Pharm. Sci.*,13(3): 571–588.
2. Nagarani,B., Ashwinkumar,K.,Srikanth, P.& Julapally, D. (2014). A Review on Controlled Drug Delivery and Brief Information on MatrixSystem.*Int. J. Innovative Pharm. Sci. Res.*, 2(7): 1555-1586.
3. Gombotz WR, Wee SF. Protein release from alginate matrices. *Adv Drug Deliv Rev* 1998; 31:267-85
4. George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: Alginate and chitosan — A review. *J Control Release*. 2006; 114:1-14
5. Wong TW, Chan LW, Kho SB, Heng PWS. Design of controlled release solid dosage forms of alginate and chitosan using microwave. *J Control Release* 2002; 84:99-114
6. Xu Y, Zhan C, Fan F, Wang L, Zheng H. Preparation of dual crosslinked alginate–chitosan blend gel beads and in vitro controlled release in oral site-specific drug delivery system. *Int J Pharm* 2007; 336:329-37
7. Singla, A.K., Chawla, M.&Singh A. (2000). Potential Applications of Carbomer in Oral Mucoadhesive Controlled Drug Delivery System: *Drug Dev. Ind. Pharm.*, 26(9): 913-924.
8. Patnaik, N.A.,Nagarjuna, T.& Thulasiramaraju, T.V. (2013). Sustained Release Drug Delivery System: A Modern Formulation Approach. *Int. J. Res. Pharm. Nano Sci.*, 2(5): 586- 601.
9. Nidhi, P., Anamika, C.,Twinkle, S., Mehul, S.,Hitesh, J.& Umesh, U.(2016). Controlled Drug Delivery System: A Review, *Indo Am. J. Pharm.*, 3(3).

10. Bhowmik, D., Gopinath, H., Kumar, B.P., Duraivel, S. & Kumar, K.P.S. (2012). Controlled Release Drug Delivery Systems. *J. Pharm. Innov.*, 1(10).
11. Nagarani, B., Ashwin, K. Parepalli, S. & Dharmendar, J. (2014) A Review on Controlled Drug Delivery and Brief Information on Matrix System. *Int. J. Innovative Pharm. Sci. Res.* 2(7):1555-1586
12. Nicholas, G. (1987). Sustained Release Dosage Forms. In: *The theory and Practice of Industrial Pharmacy*. 3rd ed., Varghese Publishing House; pp. 430-476
13. Fincher, J. H. (1968). Particle size of drugs and its relationship to absorption and activity. *J. Pharm Sci.*, 57(11):1825-1835.
14. Chien, Y.W. Controlled and modulated-release drug delivery systems. Swarbrick J, Balyan JC. *Encyclopedia of Pharmaceutical Technology*. New York: Informa Health Care. 1990., pp. 281-313
15. Jantzen, G.M. & Robinson J.R. (2002). Sustained and Controlled Release Drug Delivery System. *Mod. Pharm.*, 4th ed.; pp.507-510.
16. Poncelet D, Babak V, Dulieu C, Picot A. A physico-chemical approach to production of alginate beads by emulsification-internal ionotropic gelation. *Colloids Surfaces A: Physicochem Engineering Aspects* 1999; 155:171-6.
17. Shu XZ, Zhu KJ. The release behavior of brilliant blue from calcium alginate gel beads coated by chitosan: The preparation method effect. *Eur J Pharm Biopharm* 2002; 53:193-201.
18. Murata Y, Toniwa S, Miyamoto E, Kawashima S. Preparation of alginate gel beads containing chitosan salts and their function. *Int J Pharm* 1999; 176:265-8.
19. Murata Y, Toniwa S, Miyamoto E, Kawashima S. Preparation of alginate gel beads containing chitosan nicotinic acid salts and their functions. *Eur J Pharm Bio-pharm* 1999; 48:49-52.
20. Murata Y, Kontana Y, Ohmae H, Kawashima S. Behavior of alginate gel beads containing chitosan salts prepared with water soluble vitamins. *Eur J Pharm Bio-pharm* 2002; 53:249-51.
21. Gaudio PD, Colombo P, Colombo G, Russo P, Sonvico F. Mechanism of formation and disintegration of alginate beads obtained by prilling. *Int J Pharm* 2005; 203:1-9.
22. Available form: [http://en.wikipedia.org/wiki/Relative\\_density#Pycnometer](http://en.wikipedia.org/wiki/Relative_density#Pycnometer) [Last cited on 2011 May 12].
23. Murata Y, Sasaki N, Miyamoto E, Skawashima S. Use of floating alginate gel beads for stomach-specific drug delivery. *Eur J Pharm Bio-pharm* 2000; 50:221-6.
24. Lee BJ, Min GH. Oral controlled release of melatonin using polymerreinforced and coated alginate beads. *Int J Pharm* 1996; 144:37-46.
25. Takka S, Ocah OH, Acarturk F. Formulation and investigation of Nicardipine HCl-alginate gel beads with factorial design-based studies. *Eur J Pharm Sci* 1998; 6:241-6.
26. Fernandez-Hervas MJ, Holgado MA, Fini A, Fell JT. In vitro evaluation of alginate beads of a diclofenac salt. *Int J Pharm* 1998; 163:23-34.
27. Wong TW, Chan LW, Kho SB, Heng PW. Aging and microwave effects on alginate-chitosan matrices. *J Control Release* 2005; 104:461-5.